The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Daiichi Sankyo’s FLT3 Inhibitor Quizartinib Earns FDA’s Priority Review Status
Daiichi Sankyo said on November 22 that the US FDA has given priority review status to its FLT3 inhibitor quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML), with an action date set for May…
To read the full story
Related Article
- Quizartinib Cuts Risk of Death by 22.4% in 1st Line AML: Daiichi Sankyo
June 14, 2022
- Quizartinib Shows OS Benefit in Frontline AML, Daiichi Sankyo Mulls US/EU Filing
November 22, 2021
- Days after Japan OK, FDA Spurns Daiichi Sankyo’s Quizartinib
June 25, 2019
- FDA Extends Quizartinib Review by 3 Months: Daiichi Sankyo
April 5, 2019
BUSINESS
- Sanofi Bets on Immunotherapy to Delay Onset of Type 1 Diabetes
December 19, 2025
- Japan’s 1st Eylea Biosimilar to Reach Market on January 7
December 19, 2025
- Padcev-Keytruda Pair Makes Mark in Cisplatin-Eligible MIBC: Astellas
December 19, 2025
- Daiichi Sets February Launch for Japan’s 1st OTC Morning-After Pill
December 19, 2025
- Takeda’s TYK2 Inhibitor Scores PIII Win in Psoriasis Trials, Tops Otezla on Key Metrics
December 19, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…